Cardiology

Diabetes

Questions discussed in this category

What is the optimal BP target for patients with diabetes and hypertension to reduce their risk of MI/stroke?

1 Answer available

Are recurrent UTIs a contraindication to SGLT2i use?

4 Answers available

Should we be more cautious with the use of GLP 1 R agonist therapy in patients with Type 1 diabetes mellitus and obesity given the increased risk of cardiovascular disease with high body weight variability?

Prattichizzo et al., PMID 39468384

1 Answer available

Would you recommend statin initiation in a young adult patient (age < 40) with type 1 diabetes mellitus and LDL cholesterol levels greater than 100 without any cardiovascular risk factors?

1 Answer available

Should we recommend SGLT2i initiation at discharge to all patients hospitalized with acute myocardial infarction?

Butler et al., PMID 38587237

1 Answer available

How many days prior to surgery do you recommend stopping SGLT2 inhibitors and when is it safe to resume therapy?

1 Answer available

Do you recommend adding low-dose Aspirin for primary prevention in patients with Type 2 Diabetes on Eliquis for another indication?

1 Answer available

Does oral semaglutide provide similar cardiovascular risk reduction benefits as injectable semaglutide?

1 Answer available

How do the results of the ESPRIT trial, which evaluated the impact of an SBP target of <120 mmHg on preventing major cardiovascular events, influence your blood pressure management goals for hypertensive patients with diabetes or a history of stroke?

ESPRIT Trial

1 Answer available

Is ABI (Ankle Brachial index) lower limb arterial doppler not recommended if patient already has arterial stents in the legs, and if so, what other imaging modality would you consider as first-line?

1 Answer available

Papers discussed in this category

The New England journal of medicine, 2024 Apr 06

Empagliflozin after Acute Myocardial Infarction.

Lancet (London, England), 2024 Jun 27

Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.

The New England journal of medicine, 2016 Sep 15

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

The New England journal of medicine, 2023 Nov 11

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.

N Engl J Med, 2015 Nov 09

A Randomized Trial of Intensive versus Standard Blood-Pressure Control.

Diabetes care, 2025 Jan 01

10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2025.

Related Topics in Cardiology